Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria

Inclusion Criteria: * Age ≥ 18 years * Patient is blood group O+ * Anticipated to be hospitalized for at least 3 consecutive days after initial study transfusion * Expected to require no more than 2 units of Fresh Whole Blood in the 3 days following randomization * Agree to return to the hospital for the follow-up visits * Women of Child Bearing Potential must have a negative pregnancy test within 72 hours before randomization when warranted and must agree to practice a medically acceptable contraception regimen or agree to abstain from heterosexual intercourse during their study participation. * Patient or legally authorized representative has given written informed consent Exclusion Criteria: * Symptoms of clinical malaria (confirmed by microscopy) * Patient has received antimalarial treatment within 7 days prior to randomization * Fever (Central body temperature greater than 38.5°C) * Massive bleeding expected to require more than two Fresh Whole Blood units within 3 days from randomization * Transfusion(s) of a blood product within 1 month prior to randomization * Acute or chronic medical disorder that, in the opinion of the investigator, would impair the ability of the patient to receive protocol treatment * Previous treatment with other pathogen-reduced blood products * Females who are pregnant